Traws Pharma starts Phase 2 dosing for ratutrelvir COVID study

Traws Pharma (TRAW) announced a clinical milestone via an 8-K: on October 14, 2025, the company dosed the first subject in its Phase 2 study evaluating ratutrelvir, a ritonavir-free treatment candidate for newly diagnosed COVID subjects.

Rhea-AI Filing Summary

Traws Pharma (TRAW) announced a clinical milestone via an 8-K: on October 14, 2025, the company dosed the first subject in its Phase 2 study evaluating ratutrelvir, a ritonavir-free treatment candidate for newly diagnosed COVID subjects. The company furnished a press release as Exhibit 99.1.

This update signals progression into mid-stage testing for ratutrelvir, with details provided in the accompanying press release.

Insights

Biopharma clinical strategy analyst

R&D milestone: first Phase 2 dosing; outcomes not yet known.

Traws Pharma reports first-subject dosing in a Phase 2 study of ratutrelvir for newly diagnosed COVID subjects. Phase 2 typically evaluates dosing and signals of efficacy in a targeted patient group, indicating the program is progressing beyond initial safety assessment.

The therapy is described as ritonavir-free, positioning it within the oral antiviral landscape without pharmacokinetic boosting. The filing emphasizes forward-looking risks, so clinical benefit, safety profile, and regulatory path remain to be demonstrated.

Key next steps depend on Phase 2 readouts referenced by the program’s progression. Subsequent filings may provide data timing, endpoints, and scale of enrollment needed to assess clinical potential.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Traws Pharma (TRAW) announce in its 8-K?

The company reported dosing the first subject in a Phase 2 study of ratutrelvir for newly diagnosed COVID subjects.

What is ratutrelvir in the TRAW update?

Ratutrelvir is described as a ritonavir-free treatment candidate being evaluated for COVID.

What stage is the TRAW COVID study now in?

Phase 2, with the first subject dosed.

When did Traws Pharma dose the first Phase 2 subject?

On October 14, 2025, as disclosed in the 8-K.

Where can I find more details on the TRAW announcement?

See Exhibit 99.1, the press release furnished with the 8-K.

What ticker and exchange does Traws Pharma trade on?

Ticker TRAW on The Nasdaq Stock Market LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/14/2025 - 07:00 AM Learn about SEC filing dates

false 0001130598 0001130598 2025-10-14 2025-10-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 14, 2025

Traws Pharma, Inc.

(Exact name of Registrant as specified in its charter)

Delaware		001-36020		22-3627252
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

12 Penns Trail

Newtown, PA 18940

(267) 759-3680

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive
Offices)

Not Applicable 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $.01 per share	TRAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On October 14, 2025, Traws Pharma, Inc. (the “Company”) issued a press release (the “Press Release”) announcing the dosing of the first subject in its Phase 2 study to evaluate ratutrelvir, a ritonavir-free treatment, in newly diagnosed COVID subjects. A copy of the Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated by reference into this Item 8.01.

Forward-Looking Statements

This Current Report, including Exhibit 99.1, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions, as they relate to the Company or its management, are intended to identify such forward-looking statements.

Forward-looking statements in this Current Report, including Exhibit 99.1, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the Company involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect the Company’s business and the accuracy of the forward-looking statements contained herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated October 14, 2025.
104		Cover Page Interactive Data File (embedded within the inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 14, 2025	TRAWS PHARMA, INC.
	By:	/s/ Iain Dukes
		Iain Dukes
		Chief Executive Officer